Key facts
- Inibio’s last known valuation is $129.2M (Feb 2025).
- Notable investors include J&P Private Equity, GC Biopharma.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Inibio
- ·The full record, as it builds
Funding rounds
No funding rounds for Inibio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Inibio
Operator of a biomedical company intended to make botulinum toxin. The company specializes in medical aesthetics and develops Botox based on plant-derived ingredients, providing customers with Botox that offers proven stability and efficacy, enabling healthcare providers and global partners to access high-quality, compliant products for skin health and therapeutic applications.
- Sector
- Healthcare
- HQ
- Bucheon, South Korea
- Founded
- 2017
- Employees
- 135
- Website
- inibio.com/
- Ownership
- Privately Held (backing)
Inibio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inibio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inibio in its N-PORT filings yet. We sweep new filings monthly.